poisar

Stocks · News reference

Moderna Legal Representative Participates in AI Governance Series

Fiscal.ai

Henry Hagen from Moderna's legal department is participating in a new four-part AI governance series launched by the Practising Law Institute and the American Arbitration Association.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolAdria Cimino

    Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

    Both mRNA pioneers are transitioning beyond COVID-19 vaccine revenues. Moderna is recommended as the better buy due to growing sales, an advancing personalized cancer vaccine (intismeran) showing 42% risk reduction in melanoma trials, and an expanding vaccine portfolio. BioNTech, while having strong cash reserves and a promising pipeline, faces leadership transitions and more distant revenue opportunities.

  2. Globenewswire IncDelveinsight

    NSCLC Treatment Landscape Shifts as ESMO 2026 Spotlights MET, KRAS, and TROP2 Advances, Says DelveInsight

    The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.